Radiotherapy

MTHFR C677T and A1298C polymorphisms as predictors of radiotherapy response in head and neck squamous cell carcinoma

Q. S. Anders, Stur, E., Agostini, L. P., Garcia, F. M., Reis, R. S., Santos, J. A., Mendes, S. O., Maia, L. L., Peterle, G. T., Stange, V., Carvalho, M. B., Tajara, E. H., Santos, M., Silva-Conforti, A. M. A., and Louro, I. D., MTHFR C677T and A1298C polymorphisms as predictors of radiotherapy response in head and neck squamous cell carcinoma, vol. 14, pp. 13105-13109, 2015.

The C677T and A1298C polymorphisms in methylene­tetrahydrofolate reductase (MTHFR), which regulates the release of active folate in the body, may have reduced activity. Given that folate participates in important intracellular pathways, such as nucleotide synthesis and biomolecule methylation, it seems plausible that patients with head and neck squamous cell carcinoma (HNSCC) may respond differently to radiotherapy treatments, based on genetic polymor­phisms. Therefore, this study sought to understand the role of these polymorphisms in HNSCC patient radiotherapy response.

Subscribe to Radiotherapy